ライフサイエンスコーパス: phase II study

1 se III study), and circadian phase shifting (phase II study).

2 lone in patients with advanced melanoma in a phase II study.

3 ndent sets of serum samples in a prospective phase II study.

4 favorable changes in the lipid profile in a phase II study.

5 years) were prospectively enrolled onto this phase II study.

6 e the rationale for conducting a multicenter phase II study.

7 OS) in a randomized, controlled, and blinded phase II study.

8 d toxicity and suggestions of benefit in one phase II study.

9 ment resolution in a randomized, multicenter phase II study.

10 otecan in a multi-institutional, randomized, phase II study.

11 encouraging results in a single institution phase II study.

12 ustekinumab for psoriatic arthritis in this phase II study.

13 ally blinded, placebo-controlled, randomized phase II study.

14 xane, and capecitabine, in this multicenter, phase II study.

15 years, were treated in a limited institution phase II study.

16 Thirty-two patients were enrolled onto this phase II study.

17 This was a randomized, parallel-group, phase II study.

18 ere enrolled onto an open-label, multicenter phase II study.

19 and therapeutic efficacy were evaluated in a phase II study.

20 ly reported efficacy and safety data for the Phase II study.

21 F (mDCF) regimen in a randomized multicenter phase II study.

22 agent reported to have modest activity in a phase II study.

23 eovascularization in a previous dose-finding phase II study.

24 ted therapy were enrolled in this single-arm phase II study.

25 dvanced breast cancer in this signal-finding phase II study.

26 was not significantly superior to PC in this phase II study.

27 ract cancer (BTC, n=37) were enrolled into a phase II -study.

28 ncing the present sirolimus formulation into phase II studies.

29 a continuous dosing schedule was optimal for phase II studies.

30 atment response will be further evaluated in phase II studies.

31 sess the activity of new cytotoxic agents in phase II studies.

32 ed induction chemotherapy seems promising in phase II studies.

33 al ramifications for the predictive value of phase II studies.

34 nderstanding of the implications of positive phase II studies.

35 more effective design and interpretation of phase II studies.

36 for prophylactic use against group 2 IAVs in phase II studies.

37 gated, which have appeared superior in early phase II studies.

38 icity and definition of recommended dose for phase II studies.

39 Thirty-five patients were enrolled in this phase II study (12 in chronic phase, 17 in accelerated p

40 Of 351 phase II studies, 167 (47.6%) subsequent phase III trial

41 this prospective, double-blind, randomized, phase II study, 167 patients with refractory angina rece

42 andomized, double-blind, placebo-controlled, phase II study, 170 PsA patients with a psoriasis target

43 In this phase II study, 31 symptomatic patients age < 65 years w

44 In a phase II study, 39 healthy individuals from two US sites

45 n-label, multicenter (n = 13), parallel-arm, phase II study , 43 patients with HG BCG-refractory or r

46 Purpose Considering promising results in phase II studies, a randomized phase III trial was desig

47 In this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was adminis

48 In a randomized Phase II study, adding olaratumab to doxorubicin chemoth

49 In this single-institution phase II study, administration of 100 mCi of 131I-m81C6

50 phase III studies are a number of innovative phase II studies, aimed at bringing immunotherapy forwar

51 hemoradiotherapy has been tested in numerous phase II studies and underpowered or flawed phase III st

52 every 21 days was selected for the expanded phase II study and is preferred for future phase III stu

53 e-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were intern

54 romal tumors (GISTs) treated in a randomized phase II study and to explore the potential relationship

55 We used data from a phase II study (AOST0221) of patients with osteosarcoma

56 In this randomized phase II study, application of a single defocused shock

57 Phase II studies are ongoing.

58 Phase II studies are ongoing.

59 bjective response rates in three prospective phase II studies as first-line or second-line therapy fo

60 Two phase II studies assessed the efficacy of vismodegib, a

61 This phase II study assessed clofarabine monotherapy in older

62 This multicenter, randomized, double-blind, phase II study assessed safety and efficacy of axitinib

63 This phase II study assessed the antitumor activity of hu14.1

64 PATIENTS AND METHODS This open-label, phase II study assessed the clinical activity of everoli

65 This open-label, phase II study assessed the efficacy of vandetanib, a se

66 Our multicenter, single-arm, phase II study assessed the safety and clinical activity

67 tors should be cognizant of these factors in phase II studies before designing phase III trials.

68 must carefully be explored in well designed phase II studies before moving forward.

69 A phase II study by the Southwest Oncology Group using con

70 rituximab as part of a completed, randomized phase II study, Cancer and Leukemia Group B (CALGB) 9712

71 n-label, prospective, multicenter single-arm phase II study combined bevacizumab (BV) with radiation

72 This open-label, prospective, single-arm, phase II study combined erlotinib with radiation therapy

73 Phase II studies combining docetaxel with bevacizumab ha

74 A Phase II study comparing belatacept with cyclosporine (C

75 observations, we have initiated a randomized phase II study comparing the efficacy of standard cytoto

76 We conducted a systematic search of phase II studies conducted between 1999 and 2004 and com

77 ointing efficacy of 11betaHSD1 inhibitors in phase II studies could be explained by lack of selectivi

78 on stepwise multiple-regression analyses of phase II study data sets.

79 This phase II study demonstrates that BeGEV is an effective s

80 Results from phase II studies demonstrating a positive impact on seru

81 cine design and provides the rationale for a phase II study design using ESO(157-170) epitope or the

82 We report results of the phase II study designed to confirm this result.

83 hough several approaches have been tested in phase II study designs, few comparative data exist to gu

84 This prospective, multicenter phase II study did not specify the therapeutic regimen,

85 Adequate dose-finding phase II studies do not exist.

86 tients with relapsed refractory disease in a phase II study do not respond to PS-341.

87 The recommended phase II study dose is 12.0 mg/m2 daily CIVI for 5 days.

88 ied in the phase Ib portion (n = 7), and the phase II study enrolled 106 evaluable patients (n = 53 i

89 Patients and Methods This open-label phase II study enrolled adults with Ph(+) ALL who had re

90 was an open-label, single-arm, single-center phase II study enrolling 40 patients.

91 This phase II study evaluated efficacy and safety of single-a

92 This open-label, single-arm, phase II study evaluated efficacy and tolerability of er

93 This randomized, placebo-controlled, phase II study evaluated entinostat combined with the ar

94 This randomized phase II study evaluated ixabepilone-based chemotherapy

95 This open-label randomized phase II study evaluated progression-free survival (PFS)

96 This phase II study evaluated the activity of combined treatm

97 This multicenter, open-label, phase II study evaluated the combination of bendamustine

98 This phase II study evaluated the efficacy and safety of sora

99 This preclinical and phase II study evaluated the efficacy and safety of the

100 This single-arm phase II study evaluated the efficacy of aflibercept (VE

101 This phase II study evaluated the efficacy of bendamustine in

102 This randomized phase II study evaluated the outcome of erlotinib with a

103 This phase II study evaluated the safety and efficacy of sing

104 This prospective phase II study evaluated toxicity, relapse rate, progres

105 report results of a single-arm, multicenter, phase II study evaluating the safety and efficacy of sav

106 This phase II study examined safety and activity of panobinos

107 This phase II study examined the antitumor activity and safet

108 A single-agent phase II study examining a 200-mg dose given once every

109 -001 (EMERGE) trial is a global, multicenter phase II study examining the safety and efficacy of lena

110 In this randomized phase II study, first-line treatment with T-DM1 for pati

111 In particular, guidance on the design of phase II studies for evaluating treatments in the critic

112 ntibody that has shown clinical benefit in a phase II study for the treatment of moderate-to-severe u

113 Phase II studies from multiple rather than single instit

114 This phase II study further evaluated the safety and efficacy

115 The phase II study GO27819 investigated the monovalent MET i

116 Our previous phase II study had shown the efficacy of induction chemo

117 Patients in our single arm phase II study had stage IV NSCLC with no more than six

118 Prospective phase II studies have been reported from several contine

119 Phase II studies have demonstrated efficacy and safety w

120 Phase II studies have indicated that high rates of respo

121 served median type I error for each disease, phase II studies have positive predictive values ranging

122 Phase II studies have tested drugs blocking EGFR, vascul

123 In this phase II study, healthy adults (aged 18-64 years) who pl

124 patients with recurrent glioblastoma in this phase II study; however, further investigation into biom

125 patient was enrolled onto an investigational phase II study; however, she developed progressive disea

126 Peripheral neuropathy was assessed in two phase II studies in 256 patients with relapsed and/or re

127 mg/m(2) once-daily dosing were selected for phase II studies in children with Ph-positive leukemias.

128 These results provide the rationale for phase II studies in CLLs, lymphomas, and CD40-expressing

129 In two recently completed phase II studies in patients with relapsed Hodgkin lymph

130 Results from phase II studies in patients with stage IIIA non-small-c

131 and CRPC and may be a suitable end point for phase II studies in these settings.

132 cleoside analog, clofarabine, in two similar phase II studies in this group of patients.

133 This was a prospective phase II study in adults 18 to 59 years old with previou

134 This is the largest phase II study in chordoma to date.

135 A phase II study in lung cancer assessed the activity of i

136 This was a randomized phase II study in patients with irinotecan-refractory co

137 We conducted a proof-of-principle phase II study in patients with p53 tumor suppressor gen

138 omab therapy were evaluated in a multicenter phase II study in patients with untreated low-grade foll

139 e results, a multi-institutional neoadjuvant phase II study in resectable pancreatic cancer is planne

140 and dexamethasone is being investigated in a phase II study in this setting and in newly diagnosed MM

141 ma Group (NLG) conducted a large prospective phase II study in untreated systemic PTCL.

142 We conducted a phase II study in which patients were administered treme

143 eliminary diagnostic efficacy data from this phase II study indicate that (68)Ga-OPS202 has high sens

144 In this phase II study, intracoronary nitrite infusion did not a

145 n this article on page 1043.This multicenter phase II study investigated a selective radiotherapy dos

146 Our randomized phase II study investigated cisplatin with or without ce

147 This phase II study investigated TH-302 in combination with d

148 This phase II study investigated the activity of glembatumuma

149 This phase II study investigated the combination of TriMixDC-

150 This phase II study investigated the efficacy and safety of I

151 The recommended dose for phase II studies is 1,910 mg/m2 administered every 21 da

152 The recommended dose of CPX-351 for phase II study is 101 units/m(2).

153 A phase II study is in development.

154 omes were polysomnographic sleep efficiency (phase II study), latency to persistent sleep (phase III

155 The most common study design was a phase II study limited to previously untreated patients;

156 In this phase II study, low-dose decitabine showed promising res

157 out the del(5q) abnormality, enrolled in two phase II studies (MDS-003 and MDS-002) to determine whet

158 Data from a phase II study (n = 72) were used to model amyloid depos

159 In this phase II study (NCT00942747), temsirolimus was tested in

160 This phase II study (NCT01144455) evaluated gemcitabine plus

161 tribution from this first trial suggest that phase II studies of 131I-TM-601 are indicated.

162 On the basis of these findings, phase II studies of EC145 have been initiated in patient

163 ected at a novel therapeutic target, overuse phase II studies of FDA-approved agents, and fail to inc

164 In phase II studies of targeted agents, multiple- versus si

165 Patients were participants in two phase II studies of the recombinant MAGE-A3 antigen comb

166 e II, a phase III, and a multi-institutional phase II study of 503 patients showed that approximately

167 Phase II study of 72 patients with untreated de novo DLB

168 CONCLUSION This is the first phase II study of a new agent in sarcoma to include suff

169 We conducted a pilot phase II study of a new combined-modality paradigm of ta

170 We conducted a multicenter phase II study of a potent inhibitor of PKCbeta, enzasta

171 o chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipient

172 d the efficacy of sunitinib in a two-cohort, phase II study of advanced carcinoid and pancreatic neur

173 We therefore designed a phase II study of alisertib, a selective AAK inhibitor,

174 We conclude by calling for a prospective Phase II study of antidepressants in depressed glioma pa

175 A phase II study of ATG+G-CSF in patients with new-onset t

176 This phase II study of AUY922 and erlotinib did not meet its

177 A phase II study of bevacizumab (BVZ) plus irinotecan (CPT

178 Twenty-four children with brain tumors in a phase II study of bevacizumab and irinotecan underwent b

179 This is a phase II study of carboplatin area under the curve 5 wit

180 conducted a placebo-controlled, double-blind phase II study of carboplatin plus paclitaxel with or wi

181 We performed a phase II study of cediranib in patients with recurrent g

182 inical studies, including a large randomized phase II study of cetuximab and a randomized phase III s

183 A multicenter phase II study of cloretazine was conducted in patients

184 We conducted a phase II study of combination of the anti-insulin-like g

185 a phase I study, we performed a multicenter phase II study of daily oral sorafenib in patients with

186 A recent phase II study of enzastaurin in patients with relapsed

187 We report the results of a randomized, phase II study of erlotinib alone or intercalated with c

188 rowth factor pathway with bevacizumab (B), a phase II study of GEMOX-B was undertaken to define effic

189 RTOG 0933 was a single-arm phase II study of HA-WBRT for brain metastases with pres

190 Here, in a phase II study of HSCT for poor-prognosis multiple scler

191 his prospective, nonrandomized, multicenter, phase II study of IPI-504 monotherapy.

192 PURPOSE An international phase II study of laromustine (VNP40101M), a sulfonylhyd

193 apsed or refractory CLL were enrolled onto a phase II study of lenalidomide and rituximab.

194 e compared in this randomized, double-blind, phase II study of men with CRPC.

195 l mechanisms of this benefit, we conducted a phase II study of neoadjuvant bevacizumab (single dose)

196 We performed a phase II study of neoadjuvant chemotherapy with the obje

197 We performed a phase II study of oral vorinostat, a histone and protein

198 has previously shown antitumor activity in a phase II study of patients with advanced hereditary MTC.

199 This was an open-label, phase II study of patients with epidermal growth factor

200 We report a multicenter phase II study of patients with metastatic melanoma (MM)

201 We conducted a phase II study of pegylated interferon alfa-2a (PEG-IFN-

202 ducted a phase I and randomized double-blind phase II study of pemetrexed with ABT-751 or placebo in

203 performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor

204 We therefore performed a multicenter phase II study of rhEndostatin in patients with carcinoi

205 This phase II study of sorafenib, an oral multikinase inhibit

206 r, we systematically evaluated images from a phase II study of sunitinib, a multitargeted TKI.

207 We conducted a multicenter phase II study of the fully human IGF-1R monoclonal anti

208 A multi-institutional phase II study of this active combination is currently a

209 ed dose of ixabepilone for the initiation of phase II studies on the basis of these results is 50 mg/

210 and Methods In this multicenter, randomized, phase II study, patients with asymptomatic PCa were elig

211 In this double-blind, phase II study, patients with metastatic pancreatic canc

212 In this phase II study, patients with MF or SS with negligible t

213 In this multicenter, open-label, randomized, phase II study, patients with ovarian cancer that recurr

214 In the majority of phase II studies published to date, postconditioning evo

215 bladder-preservation studies, including five phase II studies (RTOG 8802, 9506, 9706, 9906, and 0233)

216 t eligible for further chemotherapy, and two phase II studies suggested it might be an alternative to

217 Phase II studies suggested that omitting radiotherapy de

218 A previous phase II study suggested possible clinical benefit.

219 se I evaluations, and recent evidence from a phase II study suggests that co-administration of an ant

220 In the phase II study, tasimelteon reduced sleep latency and in

221 A phase II study testing ASK1240, that is, anti-CD40 antib

222 In this open-label phase II study, TH-302 300 mg/m(2) was administered intr

223 d data from a previously reported open-label phase II study that enrolled 34 men with advanced castra

224 trial was a randomized, placebo-controlled, phase II study that enrolled patients before chemotherap

225 ity and safety study, and in 21 canines in a phase II study that included a detailed objective assess

226 hological findings of the sentinel case in a phase II study that led to clinical development disconti

227 In this two-part phase II study, the efficacy and safety of vandetanib wa

228 al therapies should involve dose-finding and phase II studies to determine the suitability of definit

229 We conducted a cooperative group phase II study to assess antitumor activity and toxicity

230 The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of ge

231 We performed an open-label phase II study to determine the safety and efficacy of P

232 We conducted a two-center phase II study to determine the safety of hemithoracic i

233 We did a phase II study to establish efficacy and physiological m

234 We conducted a phase II study to evaluate cetuximab for the treatment o

235 We performed a phase II study to evaluate the combination of imatinib m

236 We undertook this phase II study to evaluate the efficacy and safety of MD

237 We performed a phase II study to evaluate the efficacy and safety of pe

238 We performed a phase II study to evaluate the efficacy of temozolomide

239 The CLL Research Consortium initiated a phase II study to evaluate this combination in treatment

240 sly treated with trastuzumab, we conducted a phase II study to further define the safety and efficacy

241 We conducted a randomized, noncomparative phase II study to measure the efficacy of cetuximab with

242 In this double-blind, dose-escalation, phase II study, undertaken at 297 sites in 27 countries,

243 ETHODS This open-label, multi-institutional, phase II study used a two-stage design.

244 Phase I and phase II studies using oblimersen in combination with co

245 e conducted a prospective single-institution phase II study using TYMS genotyping to direct neoadjuva

246 The MTD recommended for phase II studies was 875 mg/m2/d for 5 days every 2 week

247 atelet aggregation than clopidogrel but in a phase II study was associated with increased risk for ve

248 This phase II study was conducted by the SWOG cooperative gro

249 ernational, pivotal, single-arm, open-label, phase II study was conducted in patients with stage IB t

250 A multicenter phase II study was conducted to assess the efficacy of r

251 This phase II study was conducted to confirm safety and activ

252 A phase II study was conducted to determine the efficacy a

253 A phase II study was conducted to determine the efficacy a

254 This phase II study was conducted to determine the response r

255 PURPOSE A phase II study was conducted to determine the response r

256 A prospective, open-label phase II study was conducted to determine whether donepe

257 The current multicenter phase II study was conducted to evaluate the activity an

258 A phase II study was conducted to evaluate the activity an

259 An open-label phase II study was conducted to evaluate the efficacy an

260 This phase II study was conducted to evaluate trebananib plus

261 This phase II study was conducted to further investigate the

262 A phase II study was conducted within the Pediatric Oncolo

263 This prospective phase II study was designed to assess disease control an

264 This multicenter phase II study was designed to estimate the response rat

265 This multicenter phase II study was designed to evaluate the efficacy and

266 eatment of TP53-defective CLL, a multicenter phase II study was developed to evaluate alemtuzumab and

267 double-blind, randomized, placebo-controlled phase II study was performed assessing clinical activity

268 A randomized, phase II study was performed in which patients in arm A

269 A phase II study was performed to determine the efficacy o

270 A 3:1 randomized phase II study was performed to evaluate carboplatin and

271 The dose selected for the phase II study was perifosine 50 mg/d plus bortezomib 1.

272 The purpose of this multicenter open label phase II study was to assess the efficacy and safety of

273 The primary objective of this phase II study was to characterize the safety and estima

274 The aim of this phase II study was to determine the efficacy of gemcitab

275 of this randomized, multicenter, open-label, phase II study was to determine tumor response to treatm

276 andomized, double-blind, placebo-controlled, phase II study was to evaluate the effects of denosumab

277 The goal of this phase II study was to evaluate the efficacy of this comb

278 The goal of this randomized phase II study was to evaluate two different temozolomid

279 The aim of the present phase II study was to examine virologic response rates w

280 A phase II study was undertaken in patients with recurrent

281 ENTS AND METHODS A prospective single-center phase II study was undertaken involving patients with un

282 This multicenter phase II study was undertaken to define the efficacy and

283 A randomized three-arm phase II study was undertaken to evaluate the optimum ad

284 In a single-arm phase II study we investigated the safety, efficacy, sur

285 In this phase II study, we combined cytarabine with R and B (R-B

286 In this phase II study, we investigated the efficacy and safety

287 Characteristics of the preceding phase II studies were reviewed to identify predictive fa

288 patients who received cetuximab as part of a phase II study were associated with high expression of t

289 The objectives of this phase II study were to assess the response rate and over

290 ary end point for both phase III studies and phase II studies where a delay in progression is expecte

291 neuroendocrine, colon, and breast cancers in phase II studies, whereas definitive efficacy has been d

292 h non-small-cell lung cancer in a randomized phase II study who received vandetanib, a VEGFR and epid

293 The suggested intravenous dose for a phase II study will be 1.5 mg/m2/d for 3 days.

294 Phase II studies with biomarker evaluation are ongoing.

295 Initial phase II studies with TLR-9 vaccines conjugated to a rag

296 ust therefore be on performing well-designed phase II studies with uniform sets of basic entry and ev

297 This phase II study with ER+ breast cancer patients showed th

298 This was an open-label, two-stage, phase II study with two cohorts.

299 nd in combination with chemotherapy in three phase II studies, with promising results.

300 de >/= 2 oxaliplatin-induced neuropathy in a phase II study, with 22 patients receiving i.v. mangafod